Please ensure Javascript is enabled for purposes of website accessibility

FDA Tells Intercept Pharmaceuticals No on Its NASH Drug Candidate -- for Now

By Cory Renauer – Jun 29, 2020 at 10:55AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The pharmaceutical company's attempt to get obeticholic acid approved for the lucrative non-alcoholic steatohepatitis market has hit a (perhaps temporary) roadblock.

Millions of people with a progressive liver condition will have to wait longer for a treatment for it to become available. The FDA has refused to approve an application for obeticholic acid (OCA) for patients with advanced-stage non-alcoholic steatohepatitis (NASH). Instead, the agency told the compound's owner, Intercept Pharmaceuticals (ICPT -0.21%), to try again and come back with more evidence that OCA can safely improve outcomes for people with NASH-related liver fibrosis.

Complete response letter

The FDA sent Intercept Pharmaceuticals what's called a complete response letter (CRL) asking for more evidence of the drug's efficacy and safety. This isn't an outright denial, but it does mean the company will need to produce more evidence the treatment's efficacy outweighs its potential safety issues. 

Healthcare professional holding up their hand.

Image source: Getty Images.

In its application, Intercept offered the FDA the results from its Regenerate study, which tested two different dosages of OCA among patients with different stages of NASH. In a nutshell, that study suggests that a dosage high enough to be measurably effective could also be too dangerous. 

Patients with stage 2 and 3 fibrosis treated with a high dose of OCA showed improvement in terms of liver tissue stiffness, but their NASH symptoms weren't significantly better. Unfortunately, a majority of patients treated with the effective dosage also reported chronic itching. That might not sound like such a bad trade-off for a treatment that helps with a chronic disease, but itching can be caused by a damaged liver leaking bile acids into the bloodstream, so as a symptom, it must be taken seriously here.

In May, the coronavirus pandemic led the FDA to postpone an independent advisory committee meeting to discuss Intercept's OCA application. Without briefing documents from a publicly held advisory committee meeting, we really don't know what the agency has told the company.

The contents of CRLs -- like most communications with the FDA -- aren't subject to disclosure, so the only side of this story we'll get to hear is Intercept's. The company says it believes it followed the FDA's instructions to the letter and plans to submit an updated application with additional results from the Regenerate study that haven't been reported yet.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends Intercept Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Intercept Pharmaceuticals Stock Quote
Intercept Pharmaceuticals
$14.06 (-0.21%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.